# US 2026/0216107 A1 · Interleukin-6 (il-6)/signal transducer and activator of transcription 3 (stat3) pathway inhibitors for use in the treatment of granulomatous diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216107 A1
- Document ID: US20260216107A1
- Status: Published application
- Kind: A1
- Application number: 19/151,669
- Filed: 2024-01-30
- Published: 2026-07-30
- Earliest claimed: 2023-01-30
- Assignees: UCL Business PLC
- Applicants: Ucl Business Ltd
- Inventors: Alan David SALAMA; Scott Russell HENDERSON
- Web page: https://patentgrep.com/patent/US20260216107A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07K 16/248: {IL-6}
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to the treatment of granulomatous diseases, and in particular the use of niclosamide, an IL-6 inhibitor, a STAT3 inhibitor, and/or an IL-6/STAT3 pathway inhibitor, in the treatment of a granulomatous disease.

## Claims

### Claim 1

An interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) pathway inhibitor for use in treating a granulomatous disease in a subject.

### Claim 2 (depends on 1)

The IL-6/STAT3 pathway inhibitor for use according to claim 1, wherein the inhibitor is an IL-6 inhibitor.

### Claim 3 (depends on 1)

The IL-6/STAT3 pathway inhibitor for use according to claim 1, wherein the inhibitor is a STAT3 inhibitor.

### Claim 4 (depends on 1)

The IL-6/STAT3 pathway inhibitor for use according to claim 1, wherein the inhibitor is niclosamide or a salt thereof.

### Claim 5 (depends on 1)

The IL-6/STAT3 pathway inhibitor for use according to claim 1, wherein the inhibitor is an anti-IL-6 antibody or fragment thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The IL-6/STAT3 pathway inhibitor for use according to any one of claims 1-5, wherein the granulomatous disease is Antineutrophil Cytoplasmic Antibodies (ANCA) associated vasculitis, Crohn's disease, or sarcoidosis.

### Claim 7 (depends on 6)

The IL-6/STAT3 pathway inhibitor for use according to claim 6, wherein the ANCA associated vasculitis is granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis.

### Claim 8

A method of treating a granulomatous disease in subject comprising administering an IL-6/STAT3 pathway inhibitor to the subject.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the IL-6/STAT3 pathway inhibitor is an IL-6 inhibitor.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the IL-6/STAT3 pathway inhibitor is a STAT3 inhibitor.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the IL-6/STAT3 pathway inhibitor is niclosamide or a salt thereof.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the IL-6/STAT3 pathway inhibitor is an anti-IL-6 antibody or fragment thereof.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The method according to any one of claims 8-12, wherein the granulomatous disease is Antineutrophil Cytoplasmic Antibodies (ANCA) associated vasculitis, Crohn's disease, or sarcoidosis.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the ANCA associated vasculitis is granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis.

### Claim 15

Niclosamide or a salt thereof for use in treating a granulomatous disease in a subject.

### Claim 16

A method of treating a granulomatous disease in subject comprising administering niclosamide or a salt thereof to the subject.

### Claim 17 (depends on 15, 16)

Niclosamide or a salt thereof for use according to claim 15, or the method of claim 16, wherein the granulomatous disease is Antineutrophil Cytoplasmic Antibodies (ANCA) associated vasculitis, Crohn's disease, or sarcoidosis.

### Claim 18 (depends on 17)

Niclosamide or a salt thereof for use according to claim 17, or the method of claim 17, wherein the ANCA associated vasculitis is granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis,

### Claim 19

An anti-IL-6 antibody or fragment thereof for use in treating a granulomatous disease in a subject.

### Claim 20

A method of treating a granulomatous disease in subject comprising administering an anti-IL-6 antibody or fragment thereof to the subject.

### Claim 21 (depends on 19, 20)

The anti-IL-6 antibody or fragment thereof for use according to claim 19, or the method of claim 20, wherein the granulomatous disease is Antineutrophil Cytoplasmic Antibodies (ANCA) associated vasculitis, Crohn's disease, or sarcoidosis.

### Claim 22 (depends on 21)

The anti-IL-6 antibody or fragment thereof for use according to claim 21, or the method of claim 21, wherein the ANCA associated vasculitis is granulomatosis with polyangiitis or eosinophilic granulomatosis with polyangiitis.
